The domestic equity benchmarks traded with minor cuts amid significant volatility in mid afternoon trade. The Nifty was trading a tad above the 17,650 mark. Pharma shares declined for the second consecutive trading session.
At 14:24 IST, the barometer index, the S&P BSE Sensex, was down 88.41 points or 0.15% to 60,233.96. The Nifty 50 index lost 31.75 points or 0.18% to 17,967.45.
In the broader market, the S&P BSE Mid-Cap index rose 0.10% while the S&P BSE Small-Cap index gained 0.54%.
The market breadth was almost even. On the BSE, 1634 shares rose and 1636 shares fell. A total of 144 shares were unchanged.
Buzzing Index:
The Nifty Pharma index fell 1% to 13,661.10, extending decline for second day. The index has lost 2.24% in two sessions.
Strides Pharma (down 2.72%), Ipca Laboratories (down 2.66%), Aurobindo Pharma (down 2.15%), Glenmark Pharma (down 2.02%) and Lupin (down 1.80%) edged lower.
Laurus Labs (down 1.73%), Cipla (down 1.50%), Cadila Healthcare (down 1.36%), Divi's Labs (down 1.45%), Natco Pharma (down 1.30%) and Sun Pharma (down 0.88%) declined.
However, Torrent Pharma (up 1.57%) and Granules India (up 1.48%) bucked the trend.
Biocon added 1.67% to Rs 375.50. The company's subsidiary, Biocon Biologics, and Viatris Inc. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product.
Alembic Pharmaceuticals rose 0.19% to Rs 788.50. The company said that its joint venture (JV) Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its ANDA for Mupirocin Cream USP, 2%. The cream, indicated for the treatment of secondarily infected traumatic skin lesions, has an estimated market size of US$ 28 million for twelve months ending Jun 2021 according to IQVIA.
Numbers to Track:
MCX Gold futures for 3 December 2021 settlement rose 0.13% to Rs 49,104.
The yield on India's 10-year benchmark federal paper rose to 6.362% from its previous close of 6.364%.
In the commodities market, Brent crude for January 2022 settlement lost 71 cents or 0.86% to $81.72 a barrel.
In the foreign exchange market, the partially convertible rupee rose to 74.34 from its previous closing of 74.37.
The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was currently trading flat at 95.92.
The yield on the benchmark 10-year US Treasury note last stood at 1.625% as compared to its previous close of 1.634%.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
